Overcoming Resistance and Barriers to the Use of Local Estrogen Therapy for the Treatment of Vaginal Atrophy

Overview

Journal Int J Womens Health

Publisher Dove Medical Press

Specialty Gynecology & Obstetrics

Date 2012 Oct 24

PMID 23091401

Citations 4

Authors

Lisa A Chism

Affiliations

Soon will be listed here.

Abstract

The purpose of this review is to summarize current information regarding the pathophysiology and management of vaginal atrophy (sometimes called "atrophic vaginitis") and to identify barriers to its treatment with local (or "topical") vaginal estrogen therapy. Relevant clinical trials, meta-analyses, and reviews were identified through the PubMed database. Local estrogen therapy is effective and safe for treatment of vaginal atrophy; however, barriers to treatment (eg, patient reluctance to discuss the condition, misinformation, incomplete understanding of the effectiveness and safety of available therapies) result in its underuse. Health care providers can help overcome barriers to effective treatment of vaginal atrophy by facilitating discussion with women about vaginal health. Discussions should occur at routine preventive health care examinations and during episodic visits when patients present with symptoms of vaginal atrophy. Education and counseling should include information on the importance of maintaining vaginal health and the benefits and risks of treatment, including the demonstrated effectiveness and safety profile of low-dose local estrogen therapy.

Citing Articles

Evaluating the Efficacy of Combined Intravaginal Estriol Therapy and Kegel Exercises in Managing Menopausal Atrophic Vulvovaginitis.

Serbanescu L, Rotar V, Brezeanu D, Mirea S, Ionescu E, Ionescu P Clin Pract. 2025; 15(1).

PMID: 39851803 PMC: 11763434. DOI: 10.3390/clinpract15010020.

Management of genitourinary syndrome of menopause in breast cancer survivors: An update.

Lubian Lopez D World J Clin Oncol. 2022; 13(2):71-100.

PMID: 35316932 PMC: 8894268. DOI: 10.5306/wjco.v13.i2.71.

Evaluation of the influence of chamomile vaginal gel on dyspareunia and sexual satisfaction in postmenopausal women: A randomized, double-blind, controlled clinical trial.

Bosak Z, Iravani M, Moghimipour E, Haghighizadeh M, Jelodarian P, Khazdair M Avicenna J Phytomed. 2020; 10(5):481-491.

PMID: 32995326 PMC: 7508318.

In Vitro Findings of Titanium Functionalized with Estradiol via Polydopamine Adlayer.

Steffi C, Shi Z, Kong C, Wang W J Funct Biomater. 2017; 8(4).

PMID: 28956821 PMC: 5748552. DOI: 10.3390/jfb8040045.

Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue.

Lester J, Pahouja G, Andersen B, Lustberg M J Pers Med. 2015; 5(2):50-66.

PMID: 25815692 PMC: 4493485. DOI: 10.3390/jpm5020050.

References

Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-33. DOI: 10.1001/jama.288.3.321. View

Crandall C, Petersen L, Ganz P, Greendale G . Association of breast cancer and its therapy with menopause-related symptoms. Menopause. 2004; 11(5):519-30. DOI: 10.1097/01.gme.0000117061.40493.ab. View

Ponzone R, Biglia N, Jacomuzzi M, Maggiorotto F, Mariani L, Sismondi P . Vaginal oestrogen therapy after breast cancer: is it safe?. Eur J Cancer. 2005; 41(17):2673-81. DOI: 10.1016/j.ejca.2005.07.015. View

Levine K, Williams R, Hartmann K . Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause. 2008; 15(4 Pt 1):661-6. DOI: 10.1097/gme.0b013e31815a5168. View

Dew J, Wren B, Eden J . A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric. 2003; 6(1):45-52. View

Utian W, Shoupe D, Bachmann G, Pinkerton J, Pickar J . Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001; 75(6):1065-79. DOI: 10.1016/s0015-0282(01)01791-5. View

Bond S, Horton L . Management of postmenopausal vaginal symptoms in women. J Gerontol Nurs. 2010; 36(7):3-7. DOI: 10.3928/00989134-20100527-96. View

Pruthi S, Simon J, Early A . Current overview of the management of urogenital atrophy in women with breast cancer. Breast J. 2011; 17(4):403-8. DOI: 10.1111/j.1524-4741.2011.01089.x. View

Bachmann G, Schaefers M, Uddin A, Utian W . Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2007; 110(4):771-9. DOI: 10.1097/01.AOG.0000284450.51264.31. View

10.

Boothby L, Doering P, Kipersztok S . Bioidentical hormone therapy: a review. Menopause. 2004; 11(3):356-67. DOI: 10.1097/01.gme.0000094356.92081.ef. View

11.

Kendall A, Dowsett M, Folkerd E, Smith I . Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol. 2006; 17(4):584-7. DOI: 10.1093/annonc/mdj127. View

12.

Deniz G, Antoine C, Liebens F, Carly B, Pastijn A, Rozenberg S . Treatment of premature menopause in breast cancer patients. Acta Chir Belg. 2007; 107(3):263-6. DOI: 10.1080/00015458.2007.11680053. View

13.

Nappi R, Kokot-Kierepa M . Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas. 2010; 67(3):233-8. DOI: 10.1016/j.maturitas.2010.08.001. View

14.

Johnson S, Ettinger B, Macer J, Ensrud K, Quan J, Grady D . Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstet Gynecol. 2005; 105(4):779-87. DOI: 10.1097/01.AOG.0000157116.23249.52. View

15.

Mac Bride M, Rhodes D, Shuster L . Vulvovaginal atrophy. Mayo Clin Proc. 2010; 85(1):87-94. PMC: 2800285. DOI: 10.4065/mcp.2009.0413. View

16.

Simon J, Bouchard C, Waldbaum A, Utian W, Zborowski J, Snabes M . Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2007; 109(3):588-96. DOI: 10.1097/01.AOG.0000254160.62588.41. View

17.

Simon J, Nachtigall L, Ulrich L, Eugster-Hausmann M, Gut R . Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol. 2010; 116(4):876-883. DOI: 10.1097/AOG.0b013e3181f386bb. View

18.

Eugster-Hausmann M, Waitzinger J, Lehnick D . Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. Climacteric. 2010; 13(3):219-27. DOI: 10.3109/13697137.2010.483297. View

19.

Panay N, Ylikorkala O, Archer D, Gut R, Lang E . Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric. 2007; 10(2):120-31. DOI: 10.1080/13697130701298107. View

20.

Kingsberg S, Kellogg S, Krychman M . Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy. Int J Womens Health. 2010; 1:105-11. PMC: 2971714. DOI: 10.2147/ijwh.s4872. View